Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139125 · ClinicalTrials.gov registry record · NA
An Open Trial of Cysteamine Treatment in Schizophrenia
A NA study, sponsored by Augusta University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01139125: Clinical Trial NA study, sponsored by Augusta University.
NCT01139125 is a NA study that was terminated before completion, run by Augusta University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01139125, a NA study, was terminated before completion, sponsored by Augusta University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
Primary Outcome
We are measuring if this medication is appropriate for use in schizophrenia patients.
Interventions
- DRUG (Cystagon) Cysteamine Bitartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-06 |
| Phase | NA |
Why NCT01139125 stopped before completion
NCT01139125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which (Cystagon) Cysteamine Bitartrate is the first listed.
NCT01139125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01139125 about?
NCT01139125 is a clinical study titled "An Open Trial of Cysteamine Treatment in Schizophrenia". The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
What is the current status of trial NCT01139125?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2009-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01139125?
The interventions under investigation include: (Cystagon) Cysteamine Bitartrate (DRUG).
Who is sponsoring clinical trial NCT01139125?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01139125's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia